PeriodontitisPhase 1/2NCT02337166
Regeneration of Human Intrabony Defects With rhFGF-2/HA
A Phase 1/2 study testing a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate and Periodontal flap surgery in people with Periodontitis, run by Universidade Federal Fluminense.
Trial summary
BACKGROUND: Periodontal disease is an infection that results in progressive loss of dental support, which may lead to tooth loss.. The goal of the present study was to evaluate if recombinant human Fibroblast Growth Factor type 2 (rhFGF-2) applied in periodontal intrabony defects in a hyaluronic acid (HA) carrier… Read more about this study
- Who is it for?
- Ages 35 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Periodontitis
- What is being tested?
- a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate and Periodontal flap surgery
- Type of treatment
- Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- Dec 2002to Aug 2013
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- adult subjects with chronic periodontitis presenting (b) radiographic evidence alveolar bone loss at the proximal aspect of the tooth, (c) intrabony defect deeper than 4mm, (d) probing pocket depth >6 mm at the site, (e) unremarkable general health according to medical history and clinical judgment, (f) no medications taken for at least six months and no antibiotics taken for twelve months before the beginning of the study.
Who cannot join
- subjects with "early onset" or aggressive forms of periodontitis, (b) current smokers, (c) presence of significant systemic diseases (i.e., cancer, AIDS, diabetes), (d) clinical evidence of furcation defects, (e) presence of apical radioleucency and (f) previous lack of cooperation with the maintenance program.
About this study
Official title: Regeneration of Human Intrabony Defects With Recombinant Human Fibroblast Growth Factor 2 in a Hyaluronic Acid Gel Carrier - a Longitudinal, Prospective, Randomized Controlled Clinical Trial
BACKGROUND: Periodontal disease is an infection that results in progressive loss of dental support, which may lead to tooth loss.. The goal of the present study was to evaluate if recombinant human Fibroblast Growth Factor type 2 (rhFGF-2) applied in periodontal intrabony defects in a hyaluronic acid (HA) carrier would enhance the clinical paramenters of regeneration of the periodontal attachment apparatus and the long-term maintenance of the results obtained. METHODS: Thirty adult patients were evaluated. Initial treatment consisted in plaque control measures executed previously to the experimental phase. Two intra-bony defects in each patient were ramdomly allocated for each of the treatment methods employed. Control group (n=30) were treated by open debridement with the papilla preservation flaps, while the text group (n=30) also received a topical application of rhFGF-2/HA in the intrabony defect. The parameters evaluated were, probing depth (PD), gingival recession (REC), probing attachment level (PAL) and probing bone level (PBL). Clinical measurements obtained at baseline and 1, 5 and 10 years after the surgical procedure were compared.
Read the detailed description
Study Population and Experimental Design The study was designed as a randomized, prospective, split-mouth, controlled clinical trial. It was conducted in accordance with the guidelines of the World Medical Association Declaration of Helsinki (version VI, 2002), after approval of the study design and consent by the Faculty of Medicine, Ethical Committee of Medical Research, Federal Fluminense University (Approval protocol CEP-HUAM/CCM 21/03). Written informed consent was obtained from all subjects. Systemically healthy patients with moderate to advanced chronic periodontitis referred to the Department of Periodontology, Faculty of Dentistry, Federal Fluminense University for periodontal treatment of advanced periodontitis were recruited for and treated in the study.
Inclusion criteria of the study were: (a) adult subjects with chronic periodontitis presenting (b) radiographic evidence alveolar bone loss at the proximal aspect of the tooth, (c) intrabony defect deeper than 4mm, (d) probing pocket depth >6 mm at the site, (e) unremarkable general health according to medical history and clinical judgment, (f) no medications taken for at least six months and no antibiotics taken for twelve months before the beginning of the study. Subjects who have quit the habit of smoking for at least one year before the beginning of the study were considered as non-smokers and, if the other included criteria were met, were included in the present sample. Exclusion criteria for the study were: (a) subjects with "early onset" or aggressive forms of periodontitis, (b) current smokers, (c) presence of significant systemic diseases (i.e., cancer, AIDS, diabetes), (d) clinical evidence of furcation defects, (e) presence of apical radioleucency and (f) previous lack of cooperation with the maintenance program.
Two defects were selected from each patient, and were randomly assigned, immediately before each surgical appointment, by computer generated random sequence allocation to one of the two treatment modalities employed: (a) Control: open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap; (b) Test: open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap and application of a rhFGF-2/HA in the intrabony defect. Treatment allocation was registered in an allocation table sheet that was unavailable to the clinical examiner throughout the study. Both the control and test sites were treated at the same surgical appointment and no information on treatment allocation was provided to the patient. All surgical procedures were performed by a single operator, which became aware of the site allocation only after completed root planning and conditioning, and immediately before the application of the growth factor in the test sites. A strict surgical protocol emphasizing careful hard- and soft-tissue management, root debridement, wound stability and infection control was employed (Santana et al 2009; Miranda et al 2013). Nonsurgical infection control was performed in the context of cause- related periodontal therapy and consisted of oral hygiene instructions, scaling and root planing, tooth polishing and plaque control measures performed six months prior to regenerative surgery. Patients were re-evaluated three and six months after the completion of the non-surgical cause-related periodontal therapy and enrolled following the later evaluation appointment.
Clinical Recordings Clinical parameters were assessed using the cemento-enamel junction (CEJ) or, when applicable, another defined landmark, as a fixed reference point. All measurements were recorded using an UNC #15 periodontal probe (PCP-UNC 15, Hu-Friedy, Chicago, IL, USA) by a blinded, trained and calibrated examiner (CMMS), unaware of the treatment provided at baseline and one year after treatment. Measurements were recorded to the nearest mm. Full mouth plaque score (FMPS) was recorded dichotomously as the percentage of total surfaces (four sites per tooth) (O'Leary et al. 1972). BOP was also assessed dichotomously at the same sites, and a full mouth bleeding score was calculated. Recession (REC) was measured as the distance from the CEJ to the gingival margin (GM). Probing depth (PD) was measured as the distance from the GM to the bottom of the gingival sulcus. PD and REC were used to calculate the vertical clinical attachment level (PAL). Under local anesthesia, transgingival probing was performed and the distance between the CEJ and the bottom of the defect (distance CEJ-BD) was also recorded. Clinical measurements obtained at baseline (immediately before surgery) and at twelve months are reported. After debridement of the surgical site, the bottom of the defect (BD) was defined as the distance between cemento-enamel junction and base of the defect. Bone crest level (BC) was measured as the distance between the cementoenamel junction and crest of the defect and the intra-bony defect depth (INTRA) was measured as the subtraction of BC from BD measurements (BD-BC). Moreover, the depth of the three, two and one-wall sub-components of the bony defect were also measured. The primary and secondary outcome variables of the present study were, respectively, change in PAL and bone gain (change in distance CEJ-BD).
In order to ensure the reproducibility and consistency of pre- and post-intervention measurements, examiner calibration was performed before the beginning of the study. Fourteen sites, in seven patients, with probing depths >6 mm were evaluated by the examiner on two separate occasions, 48h apart.
Flap Design Intracrevicular incisions were made and buccal and lingual mucoperiosteal flaps, including at least one tooth mesial and another distal the tooth being treated, were elevated by blunt dissection. Extreme care was taken to preserve the marginal gingiva and inter-dental tissue to achieve better closure of the treated sites. Thus, the defect-associated inter-dental papilla was accessed with papilla preservation flap techniques (Takey 1985, Cortellini et al. 1995, Cortellini et al. 1999) according to indications. A vertical releasing incision was performed at the mesial aspect of the flap whenever necessary to obtain optimized, tensionless, access to the surgical area.
Root and bone defect debridement The bone defect was meticulously debrided with surgical curettes and ultrasonic instruments with special effort to remove all the inflammatory granulation tissue, but with no intention to perforate the cortical bone walls. Thorough root planing was performed with hand (Hu-Friedy, IL, USA), rotary (Intensiv, Grancia, Switzerland) and ultrasonic instruments (Cavitron, Dentisply, USA), to remove subgingival plaque and calculus until all root surfaces attained a hard glassy surface. During the instrumentation, the flaps were slightly elevated, carefully protected with periosteal elevators, and frequently irrigated with saline.
Root conditioning and rhFGF-2 application After instrumentation, the root surfaces were washed with saline solution to remove any remaining detached fragments from the defect and surgical field. Then, a freshly prepared tetracycline hydrochloride paste in saline was applied with gentle circular movements on the instrumented and dried root surfaces of both test and control groups for three minutes. After that, the defect area was carefully rinsed with saline. Finally, on the experimental sites, 0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106 was applied on the dried root surfaces and bone defect. The flaps were then repositioned and tension-free primary flap closure was obtained using internal mattress, and single interrupted sutures (5.0 Ethicon Sutures, Johnson \& Johnson, NJ, USA or Gore-tex Sutures, W.L Gore, AZ, USA).
Post-Operative Treatment The patients were prescribed systemic antibiotic therapy consisting of 200mg of doxycycline* the day before surgery, followed by 100 mg daily continued until the 20th day after surgery. No surgical dressing was used. The patients were instructed to continue their regular home hygiene care, except in the operated area, which was cleaned by means of gentle topical applications of 0.2% chlorhexidine gluconate (Perioxidin®, Lacer, Barcelona, Spain) in saturated cotton swabs. Patients were instructed not to brush or floss the surgical area for 4 weeks, when mechanical plaque control was re-instituted. The sutures were removed two weeks after surgery. Hyper-mobile teeth were splinted either before or immediately after the surgical procedure.
Maintenance Schedule Patients were enrolled in a stringent post-operative supportive care programme following surgery (Santana et al 2009). All patients were seen weekly during the first three months and bi-weekly for the next three months. Thereafter, the patients were seen once monthly for the last six-month period of the study. After 1 year, the patients were recalled and re-instructed on proper oral hygiene. Sites were rescaled when indicated.
Radiographic assessments Radiographs were taken with a parallel, standardized, technique at baseline (Eickholz et al. 2004). Radiographs were digitized and analysed using NIH Image Analysis software. The anatomical landmarks for the study included cementum-enamel junction (CEJ), alveolar crest (AC) and base of the defect (BD) (Schei et al. 1959). Radiographic defect depth was measured along the root surface, parallel to the root axis, as the distance between CEJ and BD.
Statistical Analyses Quantitative data were recorded as mean and standard deviations. No data points were missing. Sample size was determined by Power analysis, assuming a standard deviation of the difference of 0.5, which indicated that with a sample of 20 subjects, the study would have >90% power to detect a 1-mm difference in the primary outcome measures PAL gain and CEJ-BD reduction between the two groups. In order to verify the normality of the data, the kurtosis and skewness curves were used. Because all data were considered to be normal for the parameters analysed, Student's paired t-test was used for intra-group (baseline versus 12 months) and inter-group (test versus control) comparisons. The level of significance set at 5% was used in all statistical comparisons performed in the software ProStat (Poly Software International, Pearl River, NY, USA) .
- Conditions
- Periodontitis
- Being tested
- a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate, Periodontal flap surgery
- Keywords
- alveolar bone loss, periodontal attachment loss
- Medical subject headings
- Periodontitis, Alveolar Bone Loss, Periodontal Attachment Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
a gel containing 4mg/ml rhFGF-2 in sodium hyaluronateDevice
0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106
Periodontal flap surgeryProcedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| Control | Active comparator | open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap Receives: Procedure: Periodontal flap surgery |
| Test | Experimental | open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap and application of a rhFGF-2/HA in the intrabony defect Receives: Device: a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Probing attachment level gain
Measured: up to 10 years
Bone level gain
Measured: up to 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2015 (estimated)
- Study startDec 2002
- Primary completionAug 2013
- Study completionAug 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PeriodontitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidade Federal Fluminense
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ronaldo B Santana, DDS,MScD,DSc, Principal investigator, Federal Fluminense University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02337166
- Sponsor's protocol ID
- CEP-HUAM/CCM 21/03
- Status last verified
- Jan 2015
- First submitted
- 8 Jan 2015
- Last updated
- 13 Jan 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Regeneration of Human Intrabony Defects With Recombinant Human Fibroblast Growth Factor 2 in a Hyaluronic Acid Gel Carrier - a Longitudinal, Prospective, Randomized Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT02337166
- Acronym / sponsor ID
- CEP-HUAM/CCM 21/03
- Conditions
- Periodontitis
- Keywords
- alveolar bone loss, periodontal attachment loss
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Universidade Federal FluminenseUniversity, hospital or other
- Study start
- Dec 2002
- Primary completion
- Aug 2013 (actual)
- Study completion
- Aug 2013 (actual)
- First posted
- 13 Jan 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
BACKGROUND: Periodontal disease is an infection that results in progressive loss of dental support, which may lead to tooth loss.. The goal of the present study was to evaluate if recombinant human Fibroblast Growth Factor type 2 (rhFGF-2) applied in periodontal intrabony defects in a hyaluronic acid (HA) carrier would enhance the clinical paramenters of regeneration of the periodontal attachment apparatus and the long-term maintenance of the results obtained. METHODS: Thirty adult patients were evaluated. Initial treatment consisted in plaque control measures executed previously to the experimental phase. Two intra-bony defects in each patient were ramdomly allocated for each of the treatment methods employed. Control group (n=30) were treated by open debridement with the papilla preservation flaps, while the text group (n=30) also received a topical application of rhFGF-2/HA in the intrabony defect. The parameters evaluated were, probing depth (PD), gingival recession (REC), probing attachment level (PAL) and probing bone level (PBL). Clinical measurements obtained at baseline and 1, 5 and 10 years after the surgical procedure were compared.
Detailed description
Study Population and Experimental Design The study was designed as a randomized, prospective, split-mouth, controlled clinical trial. It was conducted in accordance with the guidelines of the World Medical Association Declaration of Helsinki (version VI, 2002), after approval of the study design and consent by the Faculty of Medicine, Ethical Committee of Medical Research, Federal Fluminense University (Approval protocol CEP-HUAM/CCM 21/03). Written informed consent was obtained from all subjects. Systemically healthy patients with moderate to advanced chronic periodontitis referred to the Department of Periodontology, Faculty of Dentistry, Federal Fluminense University for periodontal treatment of advanced periodontitis were recruited for and treated in the study.
Inclusion criteria of the study were: (a) adult subjects with chronic periodontitis presenting (b) radiographic evidence alveolar bone loss at the proximal aspect of the tooth, (c) intrabony defect deeper than 4mm, (d) probing pocket depth >6 mm at the site, (e) unremarkable general health according to medical history and clinical judgment, (f) no medications taken for at least six months and no antibiotics taken for twelve months before the beginning of the study. Subjects who have quit the habit of smoking for at least one year before the beginning of the study were considered as non-smokers and, if the other included criteria were met, were included in the present sample. Exclusion criteria for the study were: (a) subjects with "early onset" or aggressive forms of periodontitis, (b) current smokers, (c) presence of significant systemic diseases (i.e., cancer, AIDS, diabetes), (d) clinical evidence of furcation defects, (e) presence of apical radioleucency and (f) previous lack of cooperation with the maintenance program.
Two defects were selected from each patient, and were randomly assigned, immediately before each surgical appointment, by computer generated random sequence allocation to one of the two treatment modalities employed: (a) Control: open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap; (b) Test: open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap and application of a rhFGF-2/HA in the intrabony defect. Treatment allocation was registered in an allocation table sheet that was unavailable to the clinical examiner throughout the study. Both the control and test sites were treated at the same surgical appointment and no information on treatment allocation was provided to the patient. All surgical procedures were performed by a single operator, which became aware of the site allocation only after completed root planning and conditioning, and immediately before the application of the growth factor in the test sites. A strict surgical protocol emphasizing careful hard- and soft-tissue management, root debridement, wound stability and infection control was employed (Santana et al 2009; Miranda et al 2013). Nonsurgical infection control was performed in the context of cause- related periodontal therapy and consisted of oral hygiene instructions, scaling and root planing, tooth polishing and plaque control measures performed six months prior to regenerative surgery. Patients were re-evaluated three and six months after the completion of the non-surgical cause-related periodontal therapy and enrolled following the later evaluation appointment.
Clinical Recordings Clinical parameters were assessed using the cemento-enamel junction (CEJ) or, when applicable, another defined landmark, as a fixed reference point. All measurements were recorded using an UNC #15 periodontal probe (PCP-UNC 15, Hu-Friedy, Chicago, IL, USA) by a blinded, trained and calibrated examiner (CMMS), unaware of the treatment provided at baseline and one year after treatment. Measurements were recorded to the nearest mm. Full mouth plaque score (FMPS) was recorded dichotomously as the percentage of total surfaces (four sites per tooth) (O'Leary et al. 1972). BOP was also assessed dichotomously at the same sites, and a full mouth bleeding score was calculated. Recession (REC) was measured as the distance from the CEJ to the gingival margin (GM). Probing depth (PD) was measured as the distance from the GM to the bottom of the gingival sulcus. PD and REC were used to calculate the vertical clinical attachment level (PAL). Under local anesthesia, transgingival probing was performed and the distance between the CEJ and the bottom of the defect (distance CEJ-BD) was also recorded. Clinical measurements obtained at baseline (immediately before surgery) and at twelve months are reported. After debridement of the surgical site, the bottom of the defect (BD) was defined as the distance between cemento-enamel junction and base of the defect. Bone crest level (BC) was measured as the distance between the cementoenamel junction and crest of the defect and the intra-bony defect depth (INTRA) was measured as the subtraction of BC from BD measurements (BD-BC). Moreover, the depth of the three, two and one-wall sub-components of the bony defect were also measured. The primary and secondary outcome variables of the present study were, respectively, change in PAL and bone gain (change in distance CEJ-BD).
In order to ensure the reproducibility and consistency of pre- and post-intervention measurements, examiner calibration was performed before the beginning of the study. Fourteen sites, in seven patients, with probing depths >6 mm were evaluated by the examiner on two separate occasions, 48h apart.
Flap Design Intracrevicular incisions were made and buccal and lingual mucoperiosteal flaps, including at least one tooth mesial and another distal the tooth being treated, were elevated by blunt dissection. Extreme care was taken to preserve the marginal gingiva and inter-dental tissue to achieve better closure of the treated sites. Thus, the defect-associated inter-dental papilla was accessed with papilla preservation flap techniques (Takey 1985, Cortellini et al. 1995, Cortellini et al. 1999) according to indications. A vertical releasing incision was performed at the mesial aspect of the flap whenever necessary to obtain optimized, tensionless, access to the surgical area.
Root and bone defect debridement The bone defect was meticulously debrided with surgical curettes and ultrasonic instruments with special effort to remove all the inflammatory granulation tissue, but with no intention to perforate the cortical bone walls. Thorough root planing was performed with hand (Hu-Friedy, IL, USA), rotary (Intensiv, Grancia, Switzerland) and ultrasonic instruments (Cavitron, Dentisply, USA), to remove subgingival plaque and calculus until all root surfaces attained a hard glassy surface. During the instrumentation, the flaps were slightly elevated, carefully protected with periosteal elevators, and frequently irrigated with saline.
Root conditioning and rhFGF-2 application After instrumentation, the root surfaces were washed with saline solution to remove any remaining detached fragments from the defect and surgical field. Then, a freshly prepared tetracycline hydrochloride paste in saline was applied with gentle circular movements on the instrumented and dried root surfaces of both test and control groups for three minutes. After that, the defect area was carefully rinsed with saline. Finally, on the experimental sites, 0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106 was applied on the dried root surfaces and bone defect. The flaps were then repositioned and tension-free primary flap closure was obtained using internal mattress, and single interrupted sutures (5.0 Ethicon Sutures, Johnson \& Johnson, NJ, USA or Gore-tex Sutures, W.L Gore, AZ, USA).
Post-Operative Treatment The patients were prescribed systemic antibiotic therapy consisting of 200mg of doxycycline* the day before surgery, followed by 100 mg daily continued until the 20th day after surgery. No surgical dressing was used. The patients were instructed to continue their regular home hygiene care, except in the operated area, which was cleaned by means of gentle topical applications of 0.2% chlorhexidine gluconate (Perioxidin®, Lacer, Barcelona, Spain) in saturated cotton swabs. Patients were instructed not to brush or floss the surgical area for 4 weeks, when mechanical plaque control was re-instituted. The sutures were removed two weeks after surgery. Hyper-mobile teeth were splinted either before or immediately after the surgical procedure.
Maintenance Schedule Patients were enrolled in a stringent post-operative supportive care programme following surgery (Santana et al 2009). All patients were seen weekly during the first three months and bi-weekly for the next three months. Thereafter, the patients were seen once monthly for the last six-month period of the study. After 1 year, the patients were recalled and re-instructed on proper oral hygiene. Sites were rescaled when indicated.
Radiographic assessments Radiographs were taken with a parallel, standardized, technique at baseline (Eickholz et al. 2004). Radiographs were digitized and analysed using NIH Image Analysis software. The anatomical landmarks for the study included cementum-enamel junction (CEJ), alveolar crest (AC) and base of the defect (BD) (Schei et al. 1959). Radiographic defect depth was measured along the root surface, parallel to the root axis, as the distance between CEJ and BD.
Statistical Analyses Quantitative data were recorded as mean and standard deviations. No data points were missing. Sample size was determined by Power analysis, assuming a standard deviation of the difference of 0.5, which indicated that with a sample of 20 subjects, the study would have >90% power to detect a 1-mm difference in the primary outcome measures PAL gain and CEJ-BD reduction between the two groups. In order to verify the normality of the data, the kurtosis and skewness curves were used. Because all data were considered to be normal for the parameters analysed, Student's paired t-test was used for intra-group (baseline versus 12 months) and inter-group (test versus control) comparisons. The level of significance set at 5% was used in all statistical comparisons performed in the software ProStat (Poly Software International, Pearl River, NY, USA) .
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | Active comparator | Procedure: Periodontal flap surgeryopen instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap |
| Test | Experimental | Device: a gel containing 4mg/ml rhFGF-2 in sodium hyaluronateopen instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap and application of a rhFGF-2/HA in the intrabony defect |
Who may qualify
- Ages
- 35 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- adult subjects with chronic periodontitis presenting (b) radiographic evidence alveolar bone loss at the proximal aspect of the tooth, (c) intrabony defect deeper than 4mm, (d) probing pocket depth >6 mm at the site, (e) unremarkable general health according to medical history and clinical judgment, (f) no medications taken for at least six months and no antibiotics taken for twelve months before the beginning of the study.
Key exclusion criteria (1 listed)
- subjects with "early onset" or aggressive forms of periodontitis, (b) current smokers, (c) presence of significant systemic diseases (i.e., cancer, AIDS, diabetes), (d) clinical evidence of furcation defects, (e) presence of apical radioleucency and (f) previous lack of cooperation with the maintenance program.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106 | Device | Test |
| Periodontal flap surgery | Procedure or surgery | Control |
Primary outcome
Probing attachment level gain
Time frame: up to 10 years
Bone level gain
Time frame: up to 10 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2015.
Related trials for Periodontitis
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Probiotics Versus Antibiotics as an Adjuvant to Non-surgical Periodontal Treatment Among Smokers With Stage II, Grade B Periodontitis
Probiotics, Antibiotics
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ronaldo B Santana, DDS,MScD,DSc principal investigator
Federal Fluminense University
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate and Periodontal flap surgery in people with Periodontitis, run by Universidade Federal Fluminense.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jan 2015. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Probing attachment level gain (time frame: up to 10 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2015.